NO20030295D0 - Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser - Google Patents

Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser

Info

Publication number
NO20030295D0
NO20030295D0 NO20030295A NO20030295A NO20030295D0 NO 20030295 D0 NO20030295 D0 NO 20030295D0 NO 20030295 A NO20030295 A NO 20030295A NO 20030295 A NO20030295 A NO 20030295A NO 20030295 D0 NO20030295 D0 NO 20030295D0
Authority
NO
Norway
Prior art keywords
valproic acid
manners
derivatives
treatment
bipolar disorders
Prior art date
Application number
NO20030295A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030295L (no
Inventor
Mitchell Shirvan
Meir Bialer
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of NO20030295D0 publication Critical patent/NO20030295D0/no
Publication of NO20030295L publication Critical patent/NO20030295L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20030295A 2000-07-21 2003-01-20 Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser NO20030295L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22010200P 2000-07-21 2000-07-21
PCT/US2001/023116 WO2002007677A2 (fr) 2000-07-21 2001-07-20 Utilisation de derives d'acide valproique et d'amides d'acide 2-valproenique pour le traitement de la manie en cas de desordre bipolaire

Publications (2)

Publication Number Publication Date
NO20030295D0 true NO20030295D0 (no) 2003-01-20
NO20030295L NO20030295L (no) 2003-01-20

Family

ID=22822065

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030295A NO20030295L (no) 2000-07-21 2003-01-20 Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser

Country Status (16)

Country Link
US (2) US6555585B2 (fr)
EP (1) EP1303289A4 (fr)
JP (1) JP2004520263A (fr)
KR (1) KR100843703B1 (fr)
CN (1) CN1251758C (fr)
AU (1) AU2001280699A1 (fr)
CA (1) CA2416821A1 (fr)
CZ (1) CZ2004266A3 (fr)
HU (1) HUP0600526A2 (fr)
IL (1) IL153942A0 (fr)
MX (1) MXPA03000547A (fr)
NO (1) NO20030295L (fr)
NZ (1) NZ523917A (fr)
PL (1) PL365588A1 (fr)
WO (1) WO2002007677A2 (fr)
ZA (1) ZA200300641B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007677A2 (fr) * 2000-07-21 2002-01-31 Teva Pharmaceutical Industries, Ltd. Utilisation de derives d'acide valproique et d'amides d'acide 2-valproenique pour le traitement de la manie en cas de desordre bipolaire
AU2003289782A1 (en) * 2002-12-16 2004-07-09 The University Of British Columbia Valproic acid analogues and pharmaceutical compositions thereof
WO2004071421A2 (fr) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Formule a liberation continue de n-(2-propylpentanoyl) glycinamide, et composes associes
WO2004071424A2 (fr) * 2003-02-05 2004-08-26 Teva Pharmaceutical Industries, Ltd. Preparation de n-(2-propylpentanoyl)glycinamide a liberation immediate
IL157751A0 (en) * 2003-02-28 2004-03-28 Yissum Res Dev Co New amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid, a method for their synthesis and pharmaceutical compositions containing them
IL156203A0 (en) * 2003-05-29 2003-12-23 Yissum Res Dev Co Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
EP1491188A1 (fr) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Utilisation topique de l'acide valproique pour traiter des maladies de la peau
US20060004098A1 (en) * 2003-07-28 2006-01-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compounds useful for treating neurological disorders
EP1713486A4 (fr) * 2003-12-02 2009-04-29 Sheldon Leslie James Therapie combinee pour le traitement de la demence, la depression et l'apathie
WO2006012603A2 (fr) * 2004-07-22 2006-02-02 Nps Pharmaceuticals, Inc. Analogues de l'isovaleramide, composition pharmaceutique contenant ces analogues et methode permettant de traiter des maladies ou des affections du systeme nerveux central
WO2007028030A2 (fr) * 2005-09-02 2007-03-08 Picobella, Llc Arn regulateurs oncogenes pour le diagnostic et la therapie
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
CN106715695B (zh) 2014-02-05 2020-07-31 耶达研究及发展有限公司 用于治疗和诊断的微rna和包含所述微rna的组合物
MX2019006940A (es) * 2016-12-14 2019-09-06 Sk Biopharmaceuticals Co Ltd Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
IL282188A (en) 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU988188A3 (ru) 1973-12-14 1983-01-07 Эсакмадьяросаги Ведьимювек (Инопредприятие) Способ получени N,N-дизамещенных амидов карбоновых кислот
DE3010599A1 (de) 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
US4301176A (en) * 1980-08-18 1981-11-17 Warner-Lambert Company Method of administering calcium valproate
FR2489319A1 (fr) * 1980-08-27 1982-03-05 Clin Midy Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant
BE885303A (fr) 1980-09-19 1981-03-19 Continental Pharma Glycinamides
LU83729A1 (fr) * 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
FI832935A (fi) 1982-08-20 1984-02-21 Midit Derivat av w-aminosyror, deras framstaellning samt dessa derivat innehaollande blandningar
US4913906B1 (en) 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
IT1190133B (it) 1986-06-19 1988-02-10 Chiesi Farma Spa Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
ATE88631T1 (de) 1986-09-17 1993-05-15 Clintec Nutrition Co Zusatznahrung bzw. therapie fuer personen mit risiko oder in behandlung fuer arteriosklerotische vaskulaere, kardiovaskulaere und/oder thrombotische erkrankungen.
US5169642A (en) * 1988-06-24 1992-12-08 Abbott Laboratories Sustained-release drug dosage units
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
CZ296263B6 (cs) 1996-03-25 2006-02-15 Eli Lilly And Company Farmaceutická kompozice pro lécení bolesti a jejípouzití
IL121268A0 (en) 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
PL345364A1 (en) 1998-06-22 2001-12-17 American Biogenetic Sciences The use of valproic acid analog for the treatment and prevention of migraine and affective illness
WO2002007677A2 (fr) * 2000-07-21 2002-01-31 Teva Pharmaceutical Industries, Ltd. Utilisation de derives d'acide valproique et d'amides d'acide 2-valproenique pour le traitement de la manie en cas de desordre bipolaire

Also Published As

Publication number Publication date
NZ523917A (en) 2004-11-26
CZ2004266A3 (cs) 2005-02-16
CA2416821A1 (fr) 2002-01-31
EP1303289A4 (fr) 2009-08-05
PL365588A1 (en) 2005-01-10
ZA200300641B (en) 2004-01-26
MXPA03000547A (es) 2004-04-05
JP2004520263A (ja) 2004-07-08
US20030212142A1 (en) 2003-11-13
US20020103237A1 (en) 2002-08-01
KR100843703B1 (ko) 2008-07-04
CN1251758C (zh) 2006-04-19
EP1303289A2 (fr) 2003-04-23
IL153942A0 (en) 2003-07-31
NO20030295L (no) 2003-01-20
CN1446097A (zh) 2003-10-01
HUP0600526A2 (en) 2006-11-28
WO2002007677A2 (fr) 2002-01-31
US6555585B2 (en) 2003-04-29
AU2001280699A1 (en) 2002-02-05
KR20030036610A (ko) 2003-05-09
WO2002007677A3 (fr) 2002-05-30

Similar Documents

Publication Publication Date Title
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
NO20030295D0 (no) Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser
NO20001754D0 (no) Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser
PL361849A1 (en) Carboxylic acid amide derivatives and their use in the treatment of thromboembolic diseases and tumours
NO20022585D0 (no) Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av CNS-forstyrrelser
HUP0104425A3 (en) Anthranilic acid amides and the use thereof for the treatment of angiogenesis
ATE455106T1 (de) Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
NO20041588L (no) Anvendelse av flibanserin ved behandling av seksuelle forstyrrelser
EE04854B1 (et) Oksabispidiinühendid, nende valmistamise meetod ning ravimvorm kasutamiseks südame arütmia raviks ja profülaktikaks
HK1045986A1 (en) Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders.
NO20031903L (no) Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
NO20032340D0 (no) Substituerte derivater av aminofuran-2-yl-eddiksyre og aminotien-2-yl-eddiksyre og deres anvendelse for behandling av migrene og smerte
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
ITMI20010957A0 (it) Derivati dell'aoe-emodina e loro impiego nel trattamento di patologieneoplastiche
EE200100527A (et) Osanetandi kasutamine meeleoluhäirete raviks kasulike ravimite valmistamiseks
EP1150669A4 (fr) Formulations a base de l-arginine utilisees dans le traitement de maladies, et leurs procedes d'utilisation
NO985974D0 (no) Piperidineddiksyrederivater og deres anvendelse ved behandling av trombose-sykdommer
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
NO20010569D0 (no) Proteaseinhibitorer for anvendelse ved behandling av psoriasis
AU2001254825A1 (en) Butenoic acids derivatives and their use in the treatment of rhinitis
DE60102471D1 (de) Indolderivate zur verwendung in der behandlung von zns-störungen
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
HK1045983A1 (en) Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders.
AU2256801A (en) Methods and compositions for use in the treatment of filovirus mediated disease conditions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application